A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)
Condition(s):Metastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine TumoursLast Updated:January 18, 2023Terminated